Brookfield Wealth Solutions Ltd.

AI-generated fair value estimate for this company.

Method: Residual income / justified price-to-tangible-book model: P/TBV = (ROE - g) / (CoE - g). Inputs: tangible book value per share of $55.66 (Sep 2026); normalized ROE of 8.4%, computed as FY2025 distributable operating earnings of $1,671M divided by tangible equity of ~$19.9B; cost of equity of 10% (diversified life/annuity and P&C insurer); long-run growth of 5%. Justified P/TBV = (8.4%-5%)/(10%-5%) = 0.68x, applied to TBVPS of $55.66.

Reasoning: The real company behind ticker BNT is Brookfield Wealth Solutions Ltd (NYSE: BNT), a ~$13B market-cap insurance/annuity and wealth-solutions holding company spun off from Brookfield in 2024, not Brainstorm Cell Therapeutics, which actually trades as BCLI on the OTCQB; for an insurance/annuity holding company a standard unlevered FCF DCF is not meaningful since reported cash flow is dominated by investment-portfolio and reserve mark-to-market swings, so a book-value-anchored residual income model using the company's own preferred distributable-earnings metric is the more standard and accurate approach.